Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 10/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402517 | 1.00 | ALDH1A1 (0.41) | ALDH1A1KMT2APOLBMAPTFOLH1 | |
| SCHEMBL20016494 | 0.87 | TSHR (0.37) | ALDH1A1KMT2APOLBMAPTTSHR | |
| SCHEMBL7911817 | 0.84 | FOLH1 (0.41) | FOLH1 | |
| SCHEMBL19062562 | 0.84 | TLR2 (0.39) | ALDH1A1KMT2AFOLH1 | |
| SCHEMBL18402488 | 0.83 | LMNA (0.38) | ALDH1A1KMT2APOLBMAPTFOLH1 | |
| SCHEMBL21415437 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KMT2APOLBMAPTTSHR | |
| SCHEMBL10904247 | 0.82 | KMT2A (0.53) | ALDH1A1KMT2APOLBMAPTTSHR | |
| SCHEMBL18402487 | 0.82 | POLB (0.46) | ALDH1A1KMT2APOLBMAPTTSHR | |
| SCHEMBL25983837 | 0.80 | MEN1 (0.50) | ALDH1A1KMT2APOLBMAPTTSHR | |
| SCHEMBL18929641 | 0.80 | PPARA (0.55) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3828275-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210130823-A1 | COMPOSITIONS AND METHODS | IONIS PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957504-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9943604-B2 | Targeted therapeutic nucleosides and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9932580-B2 | Compositions and methods for modulating HBV expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885KMT2A 2674/4885POLB 3569/4885 |
| US-20210130823-A1 | COMPOSITIONS AND METHODS | FUT6, FUT5, GNE | ALDH1A1 1681/4885KMT2A 2623/4885POLB 2978/4885 |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | ALDH1A1 1286/4885KMT2A 3611/4885POLB 4492/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | ALDH1A1 1286/4885KMT2A 3611/4885POLB 4492/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | ALDH1A1 2605/4885KMT2A 4253/4885POLB 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.